Pin32 a Public Health and Budget Impact Analysis (Bia) of Vaccinating Adults Against Pneumococcal-Diseases in Austria

Walter, E.; Eichhober, G.; Voit, M.

doi:10.1016/j.jval.2019.09.1276

Cited by 1 publication

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the Austrian record detailed in Table 3 involved a budget impact analysis of the current NIP for adults, which consists of sequential vaccination with PCV13 and PPV23 for all adults ages 50+ y. 110 A 2022 population pyramid of Austria showed that almost 42% of their population are 50+ y (about 3.7 million adults). 122 The record estimated that the VCR for this population increased by 5% points over the past 5 y, which suggests that the policy impacted the lives about 186,000 newly vaccinated people in Austria during that period.…”

Section: Discussionmentioning

confidence: 99%

“…122 The record estimated that the VCR for this population increased by 5% points over the past 5 y, which suggests that the policy impacted the lives about 186,000 newly vaccinated people in Austria during that period. 110 …”

Section: Discussionmentioning

confidence: 99%

“…47 Many of the included records discussed expansions of the risk groups included in the existing recommendations, providing further coverage for immunocompromised groups, which was then evident within reported data from Austria and France. 66 , 110 , 114 However, inconsistent trends in coverage implied that factors other than the implementation of new NIPs impact coverage.…”

Section: Discussionmentioning

confidence: 99%

“… Country Author (Ref.) Analysis type Intervention Comparator Assessment Austria Walter et al 110 BIM PCV13 or PPV23 None Positive Belgium Marbaix et al 71 CUA PCV13 None Positive Belgium Willem et al 112 CUA PPV23 PCV13+PPV23 Positive Denmark Sevilla et al 95 CA PCV13 NR Positive Denmark Birck et al 41 CEA PPV23 None Positive EU* Esposito et al 52 CA NR NR Positive Finland THL 103 CEA NR NR NR France HCSP 59 CUA PCV13+PPV23 PPV23 Positive Germany Kuchenbecker et al 67 <...…”

Section: Health Economic Evidencementioning

confidence: 99%

“…An Austrian study estimated an increase in VCR over the past 5 y from 15% to 20%, in the population aged 50+ y, and at-risk with chronic disease. 110 A French study estimated about a 9% point increase in VCR in immunocompromised adults from 2014 to 2018, but about an 8% point decrease in the overall coverage rate of at-risk adults. 114 A separate French study estimated a small decrease in the number vaccinated patients diagnosed with chronic diseases between their control and study periods.…”

Section: Vaccine Coverage Ratesmentioning

confidence: 99%

See 4 more Smart Citations

Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature

Arya,

Norton,

Kaushik

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Despite widespread use of pneumococcal vaccines throughout Europe, the burden of pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies assess the value of different vaccine schedules for protecting against PD. The aim of this review was to assess the evidence and rationales used by NITAGs/HTA agencies, when considering recent changes to National Immunization Programs (NIPs) for adults, and how identified changes affected vaccine coverage rates (VCRs). A systematic review was conducted of published literature from PubMed® and Embase®, and gray literature from HTA/NITAG websites from the last 5 y, covering 31 European countries. Evidence related to NIP recommendations, epidemiology (invasive PD, pneumonia), health economic assessments and VCRs were collected and synthesized. Eighty-four records providing data for 26 countries were identified. Of these, eight described explicit changes to NIPs for adults in seven countries. Despite data gaps, some trends were observed; first, there appears to be a convergence of NIP recommendations in many countries toward sequential vaccination, with a pneumococcal conjugate vaccine (PCV), followed by pneumococcal polysaccharide vaccine 23. Second, reducing economic or healthcare burden were common rationales for implementing changes. Third, most health economic analyses assessing higher-valency PCVs for adults found its inclusion in NIPs cost-effective. Finally, higher coverage rates were seen in most cases where countries had expanded their NIPs to cover at-risk populations. The findings can encourage agencies to improve surveillance systems and work to reach the NIP’s target populations more effectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%